(Q45711922)

15 December 2017

title

Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias (English)

1 reference

15 December 2017

0 references

0 references

1 reference

1 reference

1 reference

1

1 reference

15 December 2017

6

Thérèse Di Paolo

1 reference

15 December 2017

4

Oleh Hornykiewicz

1 reference

15 December 2017

Sam Birdi

2

1 reference

15 December 2017

Ali H Rajput

series ordinal

3

1 reference

15 December 2017

Paul J Bédard

series ordinal

5

1 reference

15 December 2017

publication date

1 February 2002

1 reference

Journal of Neuropathology & Experimental Neurology

15 December 2017

published in

1 reference

15 December 2017

volume

61

1 reference

15 December 2017

issue

2

1 reference

15 December 2017

page(s)

186-196

1 reference

Levodopa motor complications in Parkinson's disease

15 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Levodopa-induced dyskinesia: review, observations, and speculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Primate models of movement disorders of basal ganglia origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Temporal dissociation between changes in striatal enkephalin and substance P messenger RNAs following striatal dopamine depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Microcircuitry of the direct and indirect pathways of the basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Pain in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

The transcriptional regulation of the preproenkephalin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

DeltaFosB: a molecular mediator of long-term neural and behavioral plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Distribution, biochemistry and function of striatal adenosine A2A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Pre- and postmortem influences on brain RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Terminal coma affects messenger RNA detection in post mortem human temporal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

The functional anatomy of basal ganglia disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Organization of the basal ganglia: the importance of axonal collateralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Striatal neuropeptide levels in Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Parkinson's disease affects differently Met5- and Leu5-enkephalin in the human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Dopamine dependent decrease in enkephalin and substance P levels in basal ganglia regions of postmortem Parkinsonian brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Subgroups of parkinsonian patients differentiated by peptidergic immunostaining of caudate nucleus biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Met-enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Chronic MPTP treatment reduces substance P and met-enkephalin content in the basal ganglia of the marmoset

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Primate model of Parkinson's disease: alterations in multiple opioid systems in the basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Met-enkephalin immunoreactivity in the basal ganglia in symptomatic and asymptomatic MPTP-exposed monkeys: correlation with degree of parkinsonian symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Effect of an Opiate Antagonist on Movement Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F61.2.186

21 January 2018

Identifiers

DOI

10.1093/JNEN/61.2.186

1 reference

15 December 2017

1 reference